The National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health, has awarded a Fast-Track Small Business Innovation Research grant to Progentec to research the accuracy and predictive power of blood biomarker tests as a tool for measuring systemic lupus erythematosus disease activity. The tests could potentially support clinicians in selecting optimal treatment plans, adjusting medication dosing and measuring outcomes for people with lupus.
The grant will be used to validate the biomarkers and methods used in Progentec’s disease activity test, called aiSLE DX – Disease Activity Index. The project will be led by Melissa Munroe, MD, PhD, and Eldon Jupe, PhD. The test is expected to be available by the end of 2019.
Progentec Diagnostics, Inc. and Karate Health, Inc. announced today that they have merged, offering laboratory testing and digital technologies for the diagnosis and management of lupus (SLE), multiple sclerosis (MS), and other autoimmune diseases.
Progentec ... today announced it has been awarded a Fast-Track Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID). The grant funds will be released in two installments starting with a Phase I award of $225,000. In total, the grant has the potential to provide $1.7 million in non-dilutive financial resources.
Research developed by Munroe and her collaborator, fellow OMRF scientist Judith James, M.D., Ph.D., ... led them to develop an algorithm that can predict lupus disease flares up to three months in advance. The pair examined immune proteins in the blood of hundreds of lupus patients with support from the National Institutes of Health’s Autoimmunity Centers of Excellence.
Diagnostics innovator Progentec Diagnostics Inc, Oklahoma City, recently completed a second round of funding co-led by i2E and Chicago-based OCA Ventures. NMC Lifesciences, a leading global healthcare provider, also participated in the round.
Progentec also simultaneously announced the acquisition of LupusCorner, a leading patient-empowerment platform for people with systemic lupus erythematosus (SLE) and lupus nephritis. By integrating LupusCorner’s technology platform and data insights, Progentec says it is positioned to develop a first-in-class lupus-management platform.
Progentec ... today announced the completion of a second round of funding co-led by i2E and Chicago-based OCA Ventures. The funding will help bring Progentec's tool for identifying lupus flare ups and a biomarker-based disease-activity index closer to commercialization.
Progentec Diagnostics is closer to marketing a new set of tools for predicting lupus flares after obtaining $1.25 million in financing. Progentec is collaborating with Dr. Judith James, a lupus researcher who developed the technology, to refine the platform.
Progentec Diagnostics, Inc. has completed first round financing of $1.25 million. The ability to predict an impending flare represents significant value to lupus patients and their physicians. This test is currently not available and is a focus area for us,” said Sanjiv Sharma, Chairman of Progentec.
This year it’s been an across-the-board drive as i2E has closed a typical year’s worth of investments since August while helping portfolio companies clear the significant milestones that contribute to creating the groundbreaking exits of the future — companies that include Progentec Diagnostics, a startup working to provide a breakthrough diagnostic test that enables physicians to better manage the complicated and damaging autoimmune disease of lupus.